Tucidinostat/R-CHOP Combo Appears Effective, Safe in DLBCL Subtype
June 2nd 2024The addition of tucidinostat to R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2, according to interim analysis results.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Epcoritamab Regimen Yields Remission in High-Risk R/R Follicular Lymphoma
June 7th 2023The responses to epcoritamab plus rituximab/lenalidomide for patients with relapsed/refractory follicular lymphoma appear comparable between those with and without disease progression within 24 months of first-line chemotherapy in the phase 1/2 EPCORE NHL-2 trial.
Liso-Cel Yields Encouraging Responses in Relapsed/Refractory CLL/SLL
June 7th 2023Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.
Single-Agent Elranatamab Garners Robust, Durable Responses in Advanced Myeloma
June 4th 2023For the pooled analysis, investigators evaluated the efficacy and safety of bispecific antibody elranatamab in patients with relapsed/refractory multiple myeloma enrolled in 1 of the 4 MagnetisMM trials who received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 monoclonal antibody, and 1 BCMA-directed ADC and/or CAR T-cell therapy.
‘Future Is Bright’ With Bispecifics for Relapsed/Refractory Myeloma
June 3rd 2023An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.